New hope for lupus patients: two experimental drugs show promise in reducing disease activity
NCT ID NCT03656562
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 34 times
Summary
This study tested two experimental drugs, VAY736 and CFZ533, in 107 adults with systemic lupus erythematosus (SLE). The goal was to see if these drugs could reduce lupus symptoms and allow patients to lower their steroid use. Participants received either one of the drugs or a placebo, and researchers measured disease activity and safety over several months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Caba, C1015ABO, Argentina
-
Novartis Investigative Site
Clayton, Victoria, 3168, Australia
-
Novartis Investigative Site
Guangzhou, Guangdong, 510000, China
-
Novartis Investigative Site
Nanjing, Jiangsu, 210008, China
-
Novartis Investigative Site
Shanghai, 200127, China
-
Novartis Investigative Site
Prague, 128 00, Czechia
-
Novartis Investigative Site
Pessac, 33604, France
-
Novartis Investigative Site
Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
-
Novartis Investigative Site
Berlin, 10117, Germany
-
Novartis Investigative Site
Debrecen, Hajdu Bihar Megye, 4032, Hungary
-
Novartis Investigative Site
Budapest, 1023, Hungary
-
Novartis Investigative Site
Ramat Gan, 5265601, Israel
-
Novartis Investigative Site
Nagoya, Aichi-ken, 4578510, Japan
-
Novartis Investigative Site
Nagoya, Aichi-ken, 4600001, Japan
-
Novartis Investigative Site
Chuo Ku, Tokyo, 104-8560, Japan
-
Novartis Investigative Site
Shinjuku Ku, Tokyo, 162-8655, Japan
-
Novartis Investigative Site
Shinjuku-ku, Tokyo, 1608582, Japan
-
Novartis Investigative Site
Bydgoszcz, 85-168, Poland
-
Novartis Investigative Site
Poznan, 60-218, Poland
-
Novartis Investigative Site
Warsaw, 00-874, Poland
-
Novartis Investigative Site
Moscow, 115522, Russia
-
Novartis Investigative Site
Saint Petersburg, 194044, Russia
-
Novartis Investigative Site
Yekaterinburg, 620144, Russia
-
Novartis Investigative Site
Gwangju, 61469, South Korea
-
Novartis Investigative Site
Barcelona, 08035, Spain
-
Novartis Investigative Site
Barcelona, 08041, Spain
-
Novartis Investigative Site
Taichung, Taiwan ROC, 40201, Taiwan
-
Novartis Investigative Site
Taichung, 40447, Taiwan
-
Novartis Investigative Site
Taichung, 407219, Taiwan
-
Novartis Investigative Site
Bangkok, 10400, Thailand
-
Novartis Investigative Site
Bangkok, 10700, Thailand
Conditions
Explore the condition pages connected to this study.